A significant drawback is that much of the weight lost can include muscle mass, with estimates of muscle mass accounting for up to 2545% of total weight lost, which is mostly higher than with diet alone and can affect long-term health, metabolism, and strength
Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia
"There's a lot of buyer beware when it comes to compounded pharmacies," says Dr
Garveys contributions to combination therapy research include: REDEFINE 1 trial leadership Guiding the pivotal Phase 3 trial demonstrating 20.4% mean weight loss with the combination Metabolic disease pathophysiology Extensive research on insulin resistance, adipose tissue biology, and energy metabolism Clinical trial design Decades of experience leading multi-center obesity and diabetes trials Translational research Bridging basic metabolic research with clinical application Guideline development Contributing to professional society guidelines for obesity and diabetes management His work has been instrumental in establishing combination therapy approaches as the next generation of obesity pharmacotherapy, demonstrating that targeting multiple complementary pathways can produce weight loss approaching bariatric surgery outcomes